Payment overview · 2025
General Payments
$229.67
12 reported records · 9 companies
Healthcare provider profile · identity verified
Jeffrey J Green, MD
Allopathic & Osteopathic Physicians|Family Medicine · PARIS, KY · NPI 1114031937
Verified facts
What the public records show
CMS Open Payments records show Jeffrey J Green, MD received $229.67 in general payments during 2025 across 12 reported records.
Verona Pharma, Inc. accounted for 19.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lantus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $44.14 | 19.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.51 | 15.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.80 | 14.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.99 | 10.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.65 | 9.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.04 | 9.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $18.26 | 8.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.54 | 7.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.74 | 6.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $229.67 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $44.14 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 230 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 68 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
230 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 679 | 162 |
| Levothyroxine Sodium | Levothyroxine Sodium | 569 | 125 |
| Metoprolol Succinate | Metoprolol Succinate | 406 | 98 |
| Lisinopril | Lisinopril | 386 | 94 |
| Omeprazole | Omeprazole | 376 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 370 | 96 |
| Gabapentin | Gabapentin | 356 | 67 |
| Metformin Hcl | Metformin Hcl | 329 | 73 |
| Diclofenac Sodium | Diclofenac Sodium | 316 | 79 |
| Furosemide | Furosemide | 292 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 261 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 250 | 64 |
| Carvedilol | Carvedilol | 249 | 55 |
| Montelukast Sodium | Montelukast Sodium | 247 | 62 |
| Tizanidine Hcl | Tizanidine Hcl | 242 | 88 |
| Trazodone Hcl | Trazodone Hcl | 241 | 53 |
| Losartan Potassium | Losartan Potassium | 232 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 231 | 53 |
| Eliquis | Apixaban | 230 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 224 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 223 | 43 |
| Glimepiride | Glimepiride | 203 | 54 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 178 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 172 | 41 |
| Fenofibrate | Fenofibrate,micronized | 158 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 48 |
| Potassium Chloride | Potassium Chloride | 151 | 34 |
| Levofloxacin | Levofloxacin | 150 | 99 |
| Doxazosin Mesylate | Doxazosin Mesylate | 145 | 33 |
| Prednisone | Prednisone | 145 | 100 |
| Meloxicam | Meloxicam | 143 | 31 |
| Allopurinol | Allopurinol | 141 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 138 | 29 |
| Alprazolam | Alprazolam | 134 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 127 | 31 |
| Simvastatin | Simvastatin | 120 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 115 | 29 |
| Ezetimibe | Ezetimibe | 115 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 33 |
| Promethazine Hcl | Promethazine Hcl | 107 | 39 |
| Spironolactone | Spironolactone | 106 | 23 |
| Cefdinir | Cefdinir | 101 | 83 |
| Topiramate | Topiramate | 101 | 27 |
| Warfarin Sodium | Warfarin Sodium | 95 | suppressed |
| Finasteride | Finasteride | 90 | 24 |
| Famotidine | Famotidine | 83 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 83 | 18 |
| Celecoxib | Celecoxib | 82 | 18 |
| Alendronate Sodium | Alendronate Sodium | 81 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 15 |
| Glipizide Er | Glipizide | 75 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 74 | 33 |
| Meclizine Hcl | Meclizine Hcl | 74 | 28 |
| Sertraline Hcl | Sertraline Hcl | 74 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 73 | 47 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 70 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 25 |
| Jardiance | Empagliflozin | 68 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 17 |
| Gemfibrozil | Gemfibrozil | 61 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 60 | 13 |
| Ozempic | Semaglutide | 59 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 34 |
| Fenofibrate | Fenofibrate | 57 | 11 |
| Memantine Hcl | Memantine Hcl | 56 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 50 |
| Tramadol Hcl | Tramadol Hcl | 55 | 19 |
| Azithromycin | Azithromycin | 54 | 32 |
| Bupropion Xl | Bupropion Hcl | 54 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 46 |
| Temazepam | Temazepam | 53 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 41 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | suppressed |
| Atenolol | Atenolol | 51 | 11 |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 50 | 14 |
| Clonazepam | Clonazepam | 50 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 50 | 13 |
| Donepezil Hcl | Donepezil Hcl | 49 | 14 |
| Synthroid | Levothyroxine Sodium | 49 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 49 | suppressed |
| Diazepam | Diazepam | 47 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | suppressed |
| Nifedipine Er | Nifedipine | 47 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Fluconazole | Fluconazole | 46 | 28 |
| Valsartan | Valsartan | 45 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 12 |
| Metformin Hcl Er | Metformin Hcl | 44 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 43 | suppressed |
| Ibuprofen | Ibuprofen | 43 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Digoxin | Digoxin | 41 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 40 | 12 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Dexamethasone | Dexamethasone | 36 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Lansoprazole | Lansoprazole | 34 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | suppressed |
| Linzess | Linaclotide | 31 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 20 |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 29 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 28 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 19 |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Cephalexin | Cephalexin | 25 | 12 |
| Estradiol | Estradiol | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Nystatin | Nystatin | 25 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 16 |
| Valacyclovir | Valacyclovir Hcl | 25 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Indomethacin | Indomethacin | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Testosterone | Testosterone | 19 | suppressed |
| Armour Thyroid | Thyroid,pork | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 18 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 18 | suppressed |
| Ursodiol | Ursodiol | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Niacin Er | Niacin | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Entecavir | Entecavir | 13 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Neupro | Rotigotine | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Scopolamine | Scopolamine | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $229.67 · 12 records | Verona Pharma, Inc. | Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ohtuvayre, QULIPTA, TZIELD, UBRELVY, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error